Mito Energy Stack

Performance

Components

MOTS-cModerate evidence SS-31 (Elamipretide)Strong evidence NAD+ / NMNLimited evidence

Rationale

A mitochondrial triad: MOTS-c (mitochondrial peptide, AMPK — "exercise in a molecule"), SS-31 (inner-membrane cardiolipin stabilization), NAD+ as redox fuel. Goal: mitochondrial capacity and efficiency.

Evidence level

SS-31 was FDA-approved in 2025 for Barth syndrome (the first mitochondrial therapy); MOTS-c has Phase I and strong preclinical data; the combination is pure mechanism extrapolation.

Caution

No interaction data; injectable gray-market components carry contamination risk.